Willnow U
Neoplasma. 1981;28(6):721-7.
The incorporation of 3H-uridine into the RNA was studied under normothermia 37 degrees C/120 min, hyperthermia 42.5 degrees/120 min, and both in combination with Actinomycin D by an autoradiographic in vitro method in 19 solid tumors of children: 6 Wilms' tumors, 5 neuroblastomas, 4 osteogenic sarcomas, and 4 different tumors. Hyperthermia invariably reduces the 3H-uridine incorporation into RNA by 11.7--86.4%, with an average of 47.5%. Actinomycin D consistently inhibits the 3H-uridine incorporation between 27.7 and 99.8%, with the average inhibition of 62.0% being far greater than that recorded for hyperthermia. The highest degree of 3H-uridine incorporation inhibition is obtained using hyperthermia in combination with Actinomycin D. The inhibition varies from 45.5--99.8%, with an average of 81.4%. In spite of the general regularity, the effect of hyperthermia and Actinomycin D are characterized by individual patterns. Obviously, they are dependent on proliferative activity rather than upon the particular type of tumor. The use of supranormal temperatures for the treatment of malignant tumors in man, also in combination with radiation or cytostatic drugs, is a possible and promising method of therapy.
采用放射自显影体外法,在正常体温37℃/120分钟、高热42.5℃/120分钟以及二者与放线菌素D联合作用的条件下,研究了3H-尿苷掺入RNA的情况,研究对象为19例儿童实体瘤:6例肾母细胞瘤、5例神经母细胞瘤、4例骨肉瘤和4例其他不同肿瘤。高热总是使3H-尿苷掺入RNA的量减少11.7%至86.4%,平均减少47.5%。放线菌素D始终抑制3H-尿苷掺入,抑制率在27.7%至99.8%之间,平均抑制率为62.0%,远高于高热时的抑制率。高热与放线菌素D联合使用时,3H-尿苷掺入的抑制程度最高。抑制率在45.5%至99.8%之间,平均为81.4%。尽管存在一般规律,但高热和放线菌素D的作用具有个体差异。显然,它们取决于增殖活性,而非肿瘤的具体类型。将超常温度用于人类恶性肿瘤的治疗,同时联合放疗或细胞毒性药物,是一种可行且有前景的治疗方法。